AVITA Medical (RCEL) Status update summary

Business Outlook and Strategic Focus

• Emphasis on disciplined execution and predictable, forecastable growth, targeting progressive revenue increases in 2026 with a focus on execution and revenue growth.

• Strategic cost reductions and sales force optimization, focusing on 200 key accounts and prioritizing high-value burn and trauma centers.

• Product portfolio expansion includes RECELL, RECELL GO, RECELL GO mini, Cohealyx, and PermeaDerm, with ongoing efforts to drive adoption and utilization.

• International expansion underway, with trained distributors in Japan, Australia, EU, and UK, and early-stage efforts in Europe.

Financial Performance and Guidance

• Achieved $71.6 million in revenue for the year, representing 11–19% growth, with Q4 revenue at $17.6 million and 2026 revenue guidance set at $80–$85 million.

• Gross margin for the year was 82.1%, impacted by inventory reserves and product mix; expected to improve to 83–85% as RECELL outpaces other products.

• Operating expenses normalized to $23–$24 million per quarter after significant cost reductions, with FY 2025 net loss improving to $(48.6)M from $(61.8)M in FY 2024.

• Cash position supported by a $13.8M equity raise and a new $60M debt facility with improved terms, reducing cash use each quarter and supporting a path to cash flow breakeven.

Credit Facility and Covenant Management

• Transitioned from OrbiMed to a new $60 million credit facility with Perceptive Advisors, resetting revenue covenants to more achievable levels and reducing cash requirements.

• Revenue covenants for 2026 set at $73 million, well below guidance, providing headroom and reducing distractions.

• Long-term covenants (e.g., $140 million by 2030) are considered achievable with a 20%+ annual growth rate.